Devyser

Enjoyed reading our recent publications on HLA loss and immune escape after HSCT? Join our upcoming webinar to explore the science in greater depth. In the webinar: HLA loss mediated immune escape after HSCT: From biology to NGS-based detection our speaker, Claudia Durall will discuss: -Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains a major clinical challenge -Why understanding the immune escape mechanism is becoming increasingly important in post-transplant monitoring and translational research -Devyser HLA Loss, an NGS solution designed to support researchers and laboratories studying post-transplant relapse pathways Register here and learn more: https://lnkd.in/ewWVeCZM #NGS #HLAloss #Posttransplantmonitoring

A big thank you to the organizers of #ESHG2026 for another fantastic meeting in Gothenburg! We had an incredible few days filled with inspiring discussions, valuable insights from across the genetics community, and countless conversations at our booth and throughout the congress. It was a pleasure to reconnect with colleagues, partners, and customers, while also meeting many new faces. These opportunities to exchange ideas, learn from one another, and discuss the future of genetic testing are what make events like ESHG so special. Thank you to everyone who stopped by to talk with us. After three full days we left Gothenburg energized, inspired, and looking forward to continuing the conversations. Until next time! #ESHG2026 #HumanGenetics #GeneticTesting #MolecularDiagnostics

Are you still relying on Sanger sequencing for CFTR testing? Discover how laboratories are successfully transitioning to next-generation sequencing (NGS) to streamline workflows and improve diagnostic efficiency. In this webinar, Dr. Aleksandra Divac Rankov from the Institute of Molecular Genetics and Genetic Engineering (IMGGE) at the University of Belgrade will share insights on transitioning from traditional Sanger sequencing to the Devyser CFTR NGS solution. Learn how this single-tube NGS-based workflow can simplify complex testing strategies while delivering comprehensive CFTR analysis. Attend live, sign up here: https://hubs.la/Q04c5v9J0 #NGS #diagnostics #cftr #cysticfibrosis

Devyser announces the acquisition of 100 percent of the shares in CyberGene, a Swedish company within the Level Bio AB group. The acquisition strengthens Devyser’s position within the aneuploidy segment and expands the company’s offering in aneuploidy and male infertility. Cybergene AB’s portfolio complements Devyser’s existing products and is expected to have a positive impact on Devyser’s gross profit and gross margin. Commenting on the acquisition, Jan Wahlström, CEO, Devyser, stated: “We are very pleased to complete the acquisition of Cybergene AB. The transaction strengthens our product offering within aneuploidy and male infertility, while at the same time improving our gross margins.” Read more here: https://hubs.la/Q042K4lf0 This acquisition represents an important step in Devyser’s continued strategy to strengthen its market position and deliver enhanced value to customers within molecular diagnostics. Theis Kipling, Annika Ahlford, Sabina Berlin, Olle Myrberg and Ulrika Flock

Big news for genetic testing labs worldwide. Devyser has entered a strategic supply agreement with Illumina, bringing industry-leading sequencing platforms together with Devyser’s validated genetic testing solutions. Under the agreement, Devyser will be able to offer selected Illumina sequencing instruments together with Devyser’s reagent solutions, enabling customers to access advanced sequencing technology with reduced upfront capital investment. The framework is designed to simplify procurement, accelerate implementation, and support laboratories in expanding their testing capabilities. By combining Illumina’s sequencing instruments with Devyser’s reagent solutions, we’re removing barriers and making high-quality genetic testing easier to adopt than ever. This is a big step forward in delivering end-to-end, flexible testing solutions for clinical genetics and transplant diagnostics. Read the press release for more information: https://hubs.la/Q040Dn_10 Meet us at #FOG2026 or contact us if you want to learn more about how your lab can benefit from this. https://hubs.la/Q040DpfV0 Jan Wahlström and Theis Kipling #Illumina #Genomics #NGS #ClinicalGenetics #Diagnostics

Are you using the most reliable approach for CFTR testing? Our new whitepaper explores how targeted NGS offers advantages for detecting complex CFTR variants and how labs can improve turnaround time and confidence in results. Download the full whitepaper: https://hubs.la/Q03W_S9k0 #Genetics #Diagnostics #NGS #CysticFibrosis